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Abstract
The neuropeptide hormone oxytocin, which is released 
from the posterior pituitary gland, is involved in a 
number of physiological processes. Understanding of its 
effects is gradually increasing due to new research in this 
area. While mostly recognized as a reproductive system 
hormone, oxytocin also regulates other organ systems 
such as the brain and cardiovascular system. Recently, 
research has focused on unraveling its involvement in 
cancer, and emerging evidence suggests a potential 
role for oxytocin as a cancer biomarker. This review 
summarizes observations linking oxytocin and cancer, 
with a special emphasis on prostate cancer, where it 
may promote cell proliferation. Research suggests that 
oxytocin effects may depend on cell type, concentration 
of the hormone, its interactions with other hormones in 
the microenvironment, and the precise localization of 
its receptor on the cell membrane. Future research is 
needed to further elucidate the involvement of oxytocin 
in cancer, and whether it could be a clinical cancer 
biomarker or therapeutic target.
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Core tip: Oxytocin’s role outside of the reproductive 
system and social bonding has yet to be fully elucidated. 
Apparently, its role in cancer may vary depending on 
location and cell type. This review summarizes the 
current state of our understanding of the potential role 
of oxytocin in cancer.
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INTRODUCTION
Oxytocin is a central nervous system (CNS) neuropeptide 
hormone, which is composed of nine amino acids. The 
synthesis of oxytocin begins in the hypothalamus, where 
the paraventricular nucleus and supra-optic neurons 
express high levels of oxytocin, which is released from 
the posterior pituitary gland[1]. Oxytocin is biologically 
similar to vasopressin (also known as antidiuretic 
hormone), and they are often studied in parallel, as 
both hormones also share some functions. Originally 
thought of as a hormone with a role limited to the uterus 
and milk ejection - oxytocin means “quick birth” in 
Greek[2] - further research has expanded understanding 
of its function across sexes and organ systems. 
Furthermore, it has become clear that in addition to 
physical function, oxytocin also wields important impact 
on social behaviors, which include stress and trust, 
anxiety, social interaction and bonding, and parental 
care[3], and thereby on neuropsychiatric disorders 
linked to these social behaviors. Interestingly, emerging 
evidence has linked oxytocin to somewhat conflicting 
roles in carcinogenesis, as oxytocin is implicated in 
either fostering development or, conversely, inhibition of 
cancer-related cellular functional phenomena.
PHYSIOLOGICAL FUNCTIONS OF 
OXYTOCIN
Oxytocin in the reproductive system
Oxytocin exerts its effects primarily through a single 
receptor, which has been well characterized. The 
oxytocin receptor is a class-Ⅰ G-protein-coupled receptor 
with seven transmembrane domains, and can be bound 
by several ligands, including oxytocin, oxytocin agonists 
and antagonists, as well as vasopressin[4]. These re-
ceptors are found in the endometrium, myometrium, 
trophoblast, osteoblasts, reproductive organs, and 
throughout the CNS (Table 1). Notably, oxytocin receptor 
has also been implicated in various cancers related to 
tissues in which it is expressed, including endometrial 
cancer, glioblastomas, neuroblastomas[5], and others. 
Several oxytocin receptor antagonists have been 
identified, with the most common being Atosiban[6,7]. 
While studies of oxytocin antagonist in cancer has been 
limited, atosiban has been implicated in inhibiting cell 
growth of DU145 prostate cancer[8] and various breast 
cancer cell lines[9]. However, little evidence indicates 
whether this strategy is efficacious in vivo. 
The effectors of the oxytocin receptor may vary. 
While the primary signaling mechanisms of oxytocin 
have not been fully elucidated, recent studies show that 
the main mitogenic signaling mechanism of the oxytocin 
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receptor involves the Gq alpha subunit protein (Gαq)/
phospholipase C (PLC)/inositol 1, 4, 5 triphosphate 
(InsP3) pathway. Through this activation, the G protein 
couples to PLC-B, resulting in the release of calcium 
from intracellular stores[10], triggering smooth muscle 
contractions[11], for example in the uterus or in the 
myoepithelial cells of the mammary gland. The main 
oxytocin pathways described in this paper are depicted 
in Figure 1. 
Indeed, the first functional role attributed to oxytocin 
centered on the female reproductive system, specifically 
in uterine contraction and in lactation. Uterine sensitivity 
to oxytocin increases around the onset of labor, and 
upon labor oxytocin stimulation becomes more efficient. 
Therefore, exogenous administration of oxytocin is also 
clinically used to induce labor. Following parturition, the 
density of oxytocin receptors are declines. In lactation, 
the oxytocin pathway is activated when the infant begins 
sucking on the nipple[12]. A sensory impulse is sent from 
the nipple to the spinal cord, and from there transmitted 
to the oxytocinergic neurons in the hypothalamus. 
These neurons generate action potentials that lead to 
a substantial release of oxytocin into the blood stream, 
which subsequently elicits milk ejection via a contraction 
of myoepithelial cells[4]. Interestingly, this cascade can be 
triggered even before suckling occurs, by an event such 
as a baby crying[13], suggesting that it may involve reflex 
neural pathways. Increased plasma oxytocin has also 
been linked to an increased risk of pregnancy-induced 
hypertension[14], and exogenous oxytocin administration 
has been associated with angiotensin II-induced 
hypertension[15]. Interestingly, though, there is also a 
potential link between increased oxytocin and reduced 
risk of hypertension (which might be acquired in utero 
in association with intrauterine growth retardation)[16], 
so that oxytocin has been attributed with eliciting a 
reduction in blood pressure[17,18].
The reproductive function of oxytocin is not limited to 
females, as it stimulates contractility of the seminiferous 
tubules, epididymis, and the prostate gland[19]. Due to 
its production locale in the testes, oxytocin has been 
studied as a paracrine regulator of the prostate gland, 
specifically of growth and muscle contractility[20]. In 
males, oxytocin has been thought to induce erection and 
play a role in ejaculation[19,21]. Specifically, in the prostate, 
oxytocin has been suggested to induce prostatic smooth 
muscle cell contraction[22]. Its postulated involvement 
in ejaculation includes stimulation of the reproductive 
tract to promote sperm release[19]. Oxytocin’s role in 
aggravating and potentially facilitating the development 
of benign prostatic hyperplasia, and the oxytocin-induced 
proliferative effect, are likely mediated through the 
extracellular signal regulated kinase (ERK) pathway[23]. 
Oxytocin in the CNS 
Given its ubiquitous distribution in the CNS, the role of 
oxytocin in cognition and social behavior has also been 
studied extensively, especially over the past decade. 
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It has been shown that oxytocin can enhance positive 
social interactions, and importantly can enhance trust[24]. 
Oxytocin activity was found to be decreased in women 
who suffered abuse in their youth[25]. Conversely, and 
perhaps related to this, a study reported increased 
oxytocin levels in individuals enjoying heightened levels 
of partner support[26]. Oxytocin also has been reported 
to improve social cognition[27,28]. However, it must be 
noted that studies on the social effects of oxytocin are 
somewhat inconsistent[29], suggesting that at least 
socially, additional factors are likely to be at play. 
One of the aims of oxytocin research stems from an 
attempt to establish it as a tool to predict, diagnose, and 
potentially treat neuropsychiatric disorders[30], and has 
mostly focused on anxiety and depression. Oxytocin intake 
has been shown to reduce anxiety symptoms[31,32]. In 
concordance with its pivotal role during birth, the majority 
of the research regarding depression in humans has 
revolved around pregnancies and the mother’s ability to 
recover from postnatal depression (PND). Studies in this 
field have discovered lowered oxytocin in mothers with 
PND, and that increased oxytocin levels bestow positive 
effects on mothers with PND and on their interactions with 
infants[33,34]. On the other hand, abnormal post-prandial 
oxytocin secretion has also been demonstrated in women 
with anorexia nervosa, possibly as an adaptive response 
to food-related symptoms of anxiety and depression[35]. 
One of the emerging “hot topics” in neuropsychiatric 
research links oxytocin with autism[36-38], with recent 
studies beginning to identify oxytocin as a potential 
medical therapy to alleviate social anxiety caused by 
autism[39]. 
Oxytocin in the cardiovascular system
The potential regulatory role of oxytocin in other 
organ systems has also raised considerable interest. 
Oxytocin contributes to several forms of cardiovascular 
regulation, as it has been shown that preconditioning 
rats with oxytocin reduces cardiac arrhythmias[40], and 
that oxytocin can lower blood pressure[41], increase 
anti-inflammatory and antioxidant activity, and exert 
beneficial metabolic effects. Therefore, its cardiovascular 
activity seems to aim largely at restoring homeostasis.
Notably, oxytocin seems to also exert cardiovascular 
regulation during elevated levels of physical activity. 
Oxytocin levels have been shown to rise in response to 
exercise[42], which activates oxytocinergic projections[43] 
and oxytocinergic modulatory loops that adjust cardiac 
output, assisting in keeping cardiovascular control over 
the blood supply[44]. The rise in oxytocin has been traced 
to the lumbar spinal cord[45]. Oxytocin also reduces the 
rise of exercise-induced adrenocorticotropic hormone 
(ACTH) and cortisol[46,47], furthering support on its effects 
on cortisol levels. Furthermore, exogenously administered 
oxytocin along with exercise have been shown to protect 
ovariectomized rats from myocardial infarction[48]. On the 
other hand, its contribution to cardiovascular regulation 
may depend on the type or intensity of exercise, because 
plasma oxytocin in cyclists remains unchanged during 
intense exercise[49].
OXYTOCIN IN CANCER
Less is understood about the connection between 
oxytocin and cancer, partly due to lack of adequate 
research in this area, and partly due to some incon-
sistency in the current data (Figure 2). The first link of 
oxytocin to cancer was reported in 1984, when oxytocin 
was described to be structurally and genomically related 
to vasopressin, an endogenous hormone that is also 
secreted by the pituitary, and that in addition to its 
physiological functions has been found to constitute a 
biomarker of small-cell lung cancer[50]. Furthermore, 
oxytocin and vasopressin are co-expressed in these cells, 
where they have been proposed to induce mitogenic 
effects[51]. Oxytocin’s link to vasopressin and its potential 
role as a biomarker was subsequently proposed in 
1990[52]. Shortly thereafter, it was suggested that 
oxytocin may modulate growth in breast cancer[53], which 
was subsequently demonstrated[54]. These observations 
have instigated additional research into oxytocin’s 
potential involvement in various forms of cancer. 
Oxytocin in breast cancer
Interestingly, subsequent studies have shown that 
oxytocin in fact inhibits proliferation of breast cancer cell 
lines, such as MDA-MB231, MCF7, and T47D[55,56], as well 
as the canine mammary cell line CMT-U27[57], mouse 
mammary carcinoma cell line TS/A, and rat mammary 
carcinoma cell line D-R3230AC[9]. This effect was shown 
to be mediated via the cyclic adenosine monophosphate 
protein kinase A in human cell lines[58]. Importantly, anti-
proliferative and tumor inhibitory properties were also 
observed in vivo in both rat and mouse experimental 
models, and attributed to both oxytocin and its analogue 
F314[9]. Recently, it was suggested that exercise 
training, by inducing oxytocin secretion, may reduce 
the expression of specific signaling proteins involved in 
breast cancer[59].
Lactation has long been linked to a reduced risk 
Table 1  Human tissue with known expression of the oxytocin 
receptor
Tissue Expression type
Myometrium mRNA and protein[7,11] 
Lung mRNA[109]
Breast mRNA and protein[16]
Prostate mRNA[22,79] 






Blood mRNA and protein[113]
Bone mRNA[114]
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of cancer, with research dating back to as early as 
the 1950’s[60-63]. Worldwide, it has been shown that 
breastfeeding reduces the risk of both breast and uterine 
cancer, with prolonged durations of breastfeeding (usually 
involving multiple children breastfed) correlating with a 
progressive fall in the risks of both breast and uterine 
cancer[64-68]. The relationship with uterine cancer might 
be related to the action of oxytocin as a paracrine 
and endocrine hormone in lactation. Nevertheless, 
while the relationship between oxytocin, lactation, 
and breastfeeding with reduced risk of breast and 
uterine cancer are all well documented individually, 
more research needs to be conducted to determine 
if the relationship between oxytocin, lactation, and 
breastfeeding with reduced breast and uterine cancer is 
causal. Elucidating such a connection may establish new 
therapeutic targets in cancer.
Oxytocin in ovarian cancer
In addition to breast and uterine cancer, the potential 
participation of oxytocin in the pathogenesis of other 
cancers in the reproductive system has been investigated. 
Oxytocin was found to inhibit the progression of ovarian 
carcinoma (Figure 2) both in vitro and in vivo. Using 
cell viability, invasion, and migration assays, it was 
demonstrated that oxytocin inhibited proliferation, 
migration and invasion of ovarian cancer cells in vitro, 
and its administration also attenuated the dissemination 
of ovarian cancer using mean tumor burden as a 
measure[69]. The same investigators had demonstrated 
in a previous study expression of the oxytocin receptor 
in various human ovarian carcinoma tissues and cell 
lines, and identified placental leucine aminopeptidase 
(P-LAP) as an oxytocin-degrading oxytocinase in certain 
adenocarcinoma tissues[70]. This team of investigators, 
↓ Proliferation (epithelial, mesoderm, endometrium, ovarian, mammary, prostate cancer, osteosarcoma, 
breast cancer)
Oxytocin
↑ Invasion (endothelial, endometrium)
↑ Proliferation (trophoblast, endothelium, small cell lung cancer, 
Kaposi, astrocytes, myometrial, prostate, osteosarcoma, breast)
↓ Migration (head and neck squamous, endothelium, ovarian cancer, 
prostate cancer)
↑ Migration (endothelium, prostate cancer)
↓ Invasion (ovarian cancer)

























Figure 2  Mechanisms of action of oxytocin. Yellow and purple are anti-proliferation (via different subunits), red is proliferation, and blue is smooth muscle contraction. 
Gαi: Guanine nucleotide binding protein subunit alpha I; Gαs: Guanine nucleotide binding protein subunit alpha s; Gαq: Guanine nucleotide binding protein subunit 
alpha q; PI3K: Phosphoinositide 3-kinase; PLCβ: Phospholipase beta; Src: Tyrosine protein kinase; ERK: Extracellular signal-regulated kinase; p21: Cyclin-dependent 
kinase inhibitor 1; ADCY: Adenylate cyclase; cAMP: Cyclic AMP; PKA: Protein kinase A; DAG: Diacylglycerol; PKC: Protein kinase C; Insp3: Inositol triphosphate 3; 
MLCK: Myosin light chain kinase.
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therefore, proposed that a system involving P-LAP 
and oxytocin plays a role in the regulation of human 
endometrial adenocarcinoma, in which P-LAP exerts a 
functionally positive impact on carcinoma cell growth 
by degrading suppressive peptides such as oxytocin. 
More recently, these effects have also been linked 
with a cross-talk network between oxytocin and the 
stress hormone cortisol, whereby oxytocin reversed 
the carcinogenic effects of cortisol via autophagy 
(cellular self-degradation)[71]. Interestingly, pertinent 
to the postulated connection between oxytocin and 
symptoms of autism[39], oxytocin and cancer have 
also demonstrated an inverse relationship in autistic 
children[72]. 
Oxytocin in the gastrointestinal tract
Oxytocin receptors are expressed throughout the 
gastrointestinal (GI) tract[73], but little is known about 
their function in the GI tract, especially in relation to 
cancer. Some studies have suggested a link between 
oxytocin and its receptor in GI-related cancers, such 
as esophageal, gastric, and pancreatic cancers. For 
example, some studies showed an inverse relationship 
between the duration of breastfeeding and risk of 
esophageal cancer[74,75], gastric cancer[76], and pancreatic[77] 
cancer. In fact, Yu et al[78] showed a 54% decreased risk 
of developing esophageal cancer in women who breastfed 
for over 12 mo. 
Unpublished data from our laboratory shows that the 
messenger ribonucleic acid (mRNA) expression of oxytocin 
is twofold higher in PANC-1 (a human pancreatic cancer 
cell line highly unresponsive to the chemotherapeutic 
agents, gemcitabine and 5-FU) compared to L3.6pl (a 
highly responsive human pancreatic cancer cell line). We 
also found that oxytocin receptor protein expression is 
also higher in PANC-1 than in L3.6pl. Further, inhibition 
of the oxytocin receptor decreased cell proliferation of 
PANC-1 and L3.6pl cells. Our analysis of data from the 
cBioPortal database revealed that up to 5% of pancreatic 
cancer patients included in The Cancer Genome Atlas 
showed genetic alterations (primarily upregulation of 
mRNA expression) in oxytocin and its receptor. Patients 
with these alterations had poorer survival outcomes 
as compared to those without these alterations. These 
interesting data warrant further investigation on the 
molecular mechanisms implicating oxytocin and its 
receptor in pancreatic cancer and other GI cancers. 
Oxytocin in prostate cancer
As a role for oxytocin in the regulation of prostate 
function is established, its potential involvement in the 
development of prostate cancer has been proposed. 
Data from over two decades ago implicated oxytocin 
in the pathophysiology of benign prostatic hyperplasia, 
where the peptide might contribute to both the physical 
enlargement and dynamic tone of the gland[19].  More 
recently, immunohistochemical staining has detected 
oxytocin expression in stromal and epithelial cell lines and 
in tissue from patients with benign prostatic hyperplasia, 
which was significantly reduced in tissues of invasive 
prostate cancer in comparison to both benign prostatic 
hyperplasia tissues and normal human prostate epithelial 
cells[79]. This inverse relationship might implicate a fall 
in oxytocin levels in progression of prostate cancer. 
Within the prostate, oxytocin has been shown to affect 
gland growth both directly and via its interaction with 
androgen metabolism, and oxytocin concentrations 
are positively correlated with androgens[20,80]. Indeed, 
while in the absence of androgens oxytocin had no 
effect on prostate cancer cell lines (LNCaP and PC-3), 
in the presence of testosterone low oxytocin doses 
stimulated proliferation of PC-3 cells[81], supporting the 
notion that changes in levels of oxytocin in the prostate 
in aging and cancer may promote prostate epithelial 
cell proliferation. It is possible that increased levels of 
oxytocin might be involved in the mechanisms by which 
high ejaculation frequency is related to decreased risk of 
prostate cancer[82]. This hypothesis needs to be further 
investigated.
Conversely, a different study recently revealed that 
oxytocin increased the expression of APPL1, a protein 
with the ability to interact with tumor suppressor 
proteins. In vitro studies showed that oxytocin increased 
prostate cancer cell proliferation, and expression of 
APPL1. Analysis of serum and tissue samples identified 
increased oxytocin levels in the serum of prostate 
cancer patients, and high expression of oxytocin and 
its receptor in prostate tissues collected from prostate 
cancer patients in comparison to those collected from 
patients without prostate cancer. The oxytocin receptor 
has also been implicated in the migration of prostate 
cancer cells, and possibly modulation of prostate cancer 
metastasis[83]. Taken together, these observations of 
oxytocin in prostate cancer cells both in vivo and in vitro, 
suggest that oxytocin could serve as a prostate cancer 
biomarker[84]. 
Several explanations have been offered for the 
apparent differences in the data from different studies 
regarding the role of oxytocin in prostate cancer. One 
explanation is the notable difference in the numbers 
of participants involved in each study. Secondly, some 
of the studies included prostate cancer patients that 
had undergone neo-adjuvant therapy, which can affect 
oxytocin levels[85]. Thirdly, oxytocin is likely to activate 
a wide range of signaling mechanisms to elicit variable 
cellular responses, possibly depending on the density 
or precise localization of the oxytocin receptor on the 
plasma membrane[86]. This may also account for the 
dichotomy in the observations reported regarding the 
role of oxytocin in cancer. Clearly, additional studies are 
needed to elucidate the involvement of oxytocin and 
oxytocin receptor in progression or regression of human 
prostate cancer.
Perspectives and future directions 
There is clearly some evidence implicating oxytocin in 
carcinogenesis, although its precise effect and underlying 
mechanisms are still unclear. It is possible that in some 
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individuals, cell types, or types of cancers, oxytocin may 
not act as a sole regulator of carcinogenesis, but may 
mediate or modulate other coexisting factors in the 
microenvironment. 
For example, research generally supports the 
hypothesis that exercise can inhibit the progression of 
cancer[87-89]. The positive impact of exercise in blunting 
development of cancer and facilitating recovery may 
potentially be partly mediated through oxytocin. For 
example, oxytocin has been proposed to mediate an 
exercise-induced reduction in the expression of specific 
signaling molecules involved in breast cancer[59]. It has 
also recently been shown in vivo that the combination 
of exogenous oxytocin with exercise improves cardiac 
function, which might be associated with improved 
cancer survival. Cardiac dysfunction and cancer have 
such a strong link that it has even spawned its own 
subspecialty in cardio-oncology[90-93], although much of 
the research has centered around long-term survival 
and cardiac complications in cancer patients. While 
this potential mediating effect of oxytocin has been 
hypothesized[94], it appears that little primary research 
has been conducted to address this postulation. The 
ability to knockout or silence oxytocin is available, and 
its social effects are already documented[95,96]. Thus, a 
thorough study is certainly possible. Similarly, oxytocin 
may mediate the inhibitory effects of lactation on 
development of breast cancer, and of ejaculation on 
development of prostate cancer, and additional studies 
could prove to be invaluable in revealing its involvement.
It must be noted that most systems and bodily 
processes in living organisms are tightly inter-connected. 
Untangling this complexity in the presence of confounding 
elements is often difficult, especially in relation to psy-
chosocial factors. Therefore, interpretation of oxytocin’s 
expression and levels alone might be over-simplistic and 
under-informative. For example, instead of being increased 
as a direct response to exercise, oxytocin may be induced 
to assist its “companion” hormone, vasopressin, a well-
known hormonal regulator of body fluid homeostasis[97]. 
Cortisol, the “stress hormone” and the rhythm surrounding 
its release has been linked to the progression and survival 
from various cancers[98-101], and has also been linked to 
oxytocin[71,72]. The ability to completely elucidate various 
pathways and mechanisms of actions would go a long 
way to showing if the established connection between 
the different hormones extends to cancer. Furthermore, 
while outside the scope of this review, there are several 
other diseases and pathologic states possibly linked to 
oxytocin. Pain, depression, and anxiety have all been 
linked to oxytocin[102,103]. Oxytocin’s role in depression 
management was mentioned previously in this article, 
but oxytocin also seems to be a promising target in pain 
management[104-107], and in immunotherapy, especially 
through its interactions in the gut[108].
CONCLUSION
Most knowledge of oxytocin centers on its role as a 
reproductive hormone. Since its discovery, its other 
roles have progressively become clearer, including 
involvement in social behavior, cardiovascular regu-
lation, and carcinogenesis. While it is currently difficult 
to pinpoint and precisely define oxytocin’s oncogenic 
roles, it is hoped that this review will encourage greater 
intensity in researching the details of the role of oxytocin 
in cancer. Future research has a number of plausible 
and exciting directions to follow and will hopefully clarify 
some of the ambiguities concerning the role of oxytocin 
in cancer. 
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